Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Phase 4, Multicenter, Randomized, Open-Lable, Active-Controlled Study of the Efficacy and Safty of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in Incident-Dialysis Patients

The purpose of the study is to determin whether HIF-PHI is safe and effective in the treatment of anemia and meanwhile reduces the risk of cardiovascular and cerebrovascular events in patients who have just initiated dialysis.

Study Overview

• Status: Not yet recruiting
• Conditions: Anemia in Incident Dialysis Patients
• Intervention / Treatment: Drug: HIF-PHI; Drug: Epoetin Alfa

Detailed Description

There is a screening period of up to 2 weeks, a treatment period of a minimum of 52 weeks and a maximum of approximately up to 3 years after last patient is randomized. A total of up to 400 patients will be randomized in a 1:1 ratio to receive either open-lable HIF-PHI or Active Control (Epoetin alfa).

• Study Type: Interventional
• Enrollment (Anticipated): 400
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410000
      • Department of Nephrology, Second Xiangya Hospital, Central South University
      • Contact: Hong Liu, MD,phD; Phone Number: 86-0731-85292057; Email: liuh0618@163.com
      • Principal Investigator: Hong Liu, MD,phD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The patient or his/her legal guardian signs the informed consent
2. Age ≥18 years
3. Weight: 45-100 kg (included)
4. Patients with CKD end-stage renal disease received hemodialysis treatment ≤ 4 weeks, dialysis frequency was stable, kt / V ≥ 1.2, and planned to continue dialysis treatment during the study period
5. No iron deficiency.
6. No folate or Vitamin B12 deficiency.
7. No abnormal liver tests.
8. During the screening period, value of Hb is less than 10. 0 g / dl.

Exclusion Criteria:

1. Evidence of any clinically significant infection or active potential infection;
2. Active hepatitis or any of the following abnormalities (ALT ≥ 2 times the upper limit of normal value, AST ≥ 2 times the upper limit of normal value, DBIL ≥ 2 times the upper limit of normal value);
3. Patients with severe cardiovascular disease have had myocardial infarction, coronary artery bypass or PCI operation within 3 months prior to participating in the study.
4. Patients have experienced severe cerebrovascular diseases within 3 months prior to participating in the study: stroke; obvious neurological dysfunction after stroke;
5. Patients with active gastrointestinal bleeding occurred within 3 months prior to participating in the study.
6. Poor control of hypertension determined by the researchers;
7. Previous or current malignancies (except for excised non melanoma skin cancer and carcinoma in situ);
8. It is known to have blood system diseases (including congenital and postnatal diseases, such as thalassemia, Fanconi anemia, aplastic anemia, myelodysplastic syndrome, hemolytic anemia, coagulation dysfunction, etc.) or other causes of anemia (such as fecal occult blood positive gastrointestinal hemorrhage or hookworm disease, etc.) ;
9. Known autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, anti neutrophil cytoplasmic antibody associated vasculitis, etc.);
10. Any previous functional organ transplant or scheduled organ transplant or no kidney.
11. Elective surgery that is expected to result in significant blood loss during the study period.
12. Serum albumin < 25 g / L;
13. Within 8 weeks before administration on the first day, the patients were treated with androgen, deferoxamine, deferrone or deferestrol.
14. Life expectancy < 12 months;
15. Transfusion within 4 weeks before administration on day 1, or is expected.
16. Intravenous iron supplementation and / or unwillingness to stop intravenous iron injection during the screening period;
17. Patients with drug abuse or addiction;
18. Have received any test drug within 4 weeks before inclusion or plan to receive other drug tests during the trial;
19. Women who can become pregnant must use contraception. Men with sexual partners who can become pregnant must use birth control, unless the man agrees to use contraception.
20. Any medical condition, that in the opinion of the study doctor, may pose a safety risk to the patient, may confound efficacy or safety assessment, or may interfere with study participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HIF-PHI; HIF-PHI will be dosed orally three times a week.	Drug: HIF-PHI; Drug will be dosed orally three times a week.
Active Comparator: Epoetin alfa; Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.	Drug: Epoetin Alfa; The drug will be dispensed per the package insert or the country-specific product labeling.; Other Names: Epogen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Hemoglobin (Hb) change from baseline to average levels from Week 28 to Week 52.	For participants who did not have an available Hb value during the week 28-52 period, imputation rules were applied.	Minimum of 52 weeks and maximum of up to 3 years after last subject is randomized
Proportion of subjects who achieve a Hb response during the first 24 weeks of treatment.	A Hb response is defined as: Hb ≥11.0g/dL and a Hb increase from baseline by ≥1.0g/dL in subjects whose baseline Hb >8.0g/dL, or Increase in Hb ≥2.0g/dL in subjects whose baseline Hb ≤8.0g/dL.	Week 0 to Week 24
The incidence of cardiovascular and cerebrovascular events within 52 weeks.	Non fatal myocardial infarction, unstable angina, coronary artery bypass, coronary or peripheral vascular intervention, hospitalization due to heart failure, transient ischemic attack, stroke and death.	Week 0 to Week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All cause mortality	The incidence of death events.	Minimum of 52 weeks and maximum of up to 3 years after last subject is randomized
BP effect 1: the proportion of subjects with increased hypertension	Blood pressure (BP) increased compared to pre-dialysis BP: the delta systolic BP ≥ 20 mmHg and systolic blood pressure ≥ 170 mmHg, or the delta diastolic BP ≥ 15 mmHg and diastolic BP ≥ 100 mmHg.	Week 0 to Week 27
BP effect 2	Mean BP change from baseline to average levels from Week 28 to Week 52.	Week 28 to Week 52
The change of left ventricular structure	Standardized ECHO evaluates left ventricular volume index (ml/m2).	Weeks 12, 36, 52
The change of left ventricular systolic function	Standardized ECHO evaluates left ventricular ejection fraction (%).	Weeks 12, 36, 52
The change of right ventricular systolic function	Systolic lateral tricuspid annulus velocity (S') was measured by tissue Doppler.	Weeks 12, 36, 52
The change of diastolic function	Left ventricular diastolic function was measured based on the integration of the ratio of early (E wave) and late (A wave) mitral inflow, mitral E wave deceleration time, E/e' ratio (e' being the tissue Doppler velocity of the medial annulus), E/A changes with Valsalva maneuver, and pattern of pulmonary vein flow. The data will be combine to report diastolic function.	Weeks 12, 36, 52
Serum lipid parameters	Mean change in low-density lipoprotein (LDL) cholesterol.	Week 25 to Week 27
Inflammatory evaluation 1	Mean change level of CRP.	Week 25 to Week 27
Inflammatory evaluation 2	Mean change level of IL-2	Week 25 to Week 27
Inflammatory evaluation 3	Mean change level of IL-6	Week 25 to Week 27
Inflammatory evaluation 4	Mean change level of IL-17A	Week 25 to Week 27

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum iron level	Mean change of iron from baseline to level at the 27th week.	Week 0 to Week 27

Collaborators and Investigators

• Sponsor: Second Xiangya Hospital of Central South University

Publications and helpful links

General Publications

• Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.

Study record dates

Study Major Dates

• Study Start (Anticipated): October 20, 2022
• Primary Completion (Anticipated): October 19, 2023
• Study Completion (Anticipated): October 19, 2024

Study Registration Dates

• First Submitted: October 16, 2019
• First Submitted That Met QC Criteria: October 17, 2019
• First Posted (Actual): October 21, 2019

Study Record Updates

• Last Update Posted (Actual): May 25, 2021
• Last Update Submitted That Met QC Criteria: May 20, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Anemia; Hematinics; Epoetin Alfa
• Other Study ID Numbers: CSU-SXH-CT-2019-015

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No